Rights and permissions
About this article
Cite this article
Alemtuzumab: a costly alternative in CLL?. Pharmacoecon. Outcomes News 605, 12 (2010). https://doi.org/10.2165/00151234-201006050-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006050-00017